Research Article

The Efficacy of Plantago major Seed on Liver Enzymes in Nonalcoholic Fatty Liver Disease: A Randomized Double-Blind Clinical Trial

Table 2

Comparing biochemical parameters and NAFLD grades at the baseline and after 12 weeks in P. major and placebo group.

VariablesGroupBaseline value1After 12 weeks valuePercent change value1

ALT (IU/L)P. major79.87 ± 36.190.06847.32 ± 21.770.47435.94 ± 22.820.042
Placebo66.37 ± 25.5450.03 ± 21.1919.53 ± 28.72

AST (IU/L)P. major43.77 ± 17.240.10628.29 ± 10.490.3929.59 ± 24.310.004
Placebo37.93 ± 16.8032.03 ± 13.3012.09 ± 19.97

FBS (mg/dl)P. major99.0 ± 12.020.429103.93 ± 14.410.079−5.48 ± 12.850.67
Placebo100.43 ± 25.8103.62 ± 41.95−2.59 ± 15.23

Cholesterol (mg/dl)P. major190.83 ± 42.720.559183.12 ± 42.860.7263.27 ± 15.050.157
Placebo189.65 ± 35.49185.68 ± 33.841.60 ± 7.65

TG (mg/dl)P. major230.03 ± 108.020.063200.93 ± 106.740.9296.81 ± 36.450.001
Placebo181.31 ± 77.33183.75 ± 73.96−5.07 ± 23.97

HDL (mg/dl)P. major40.19 ± 7.110.02942.67 ± 6.710.05−7.73 ± 17.040.433
Placebo36.12 ± 4.0339.37 ± 5.03−9.46 ± 12.74

LDL (mg/dl)P. major104.90 ± 32.550.036106.41 ± 33.240.466−4.79 ± 33.390.326
Placebo114.03 ± 26.68108.62 ± 25.724.27 ± 8.56

PlateletP. major218.03 ± 63.500.038213.09 ± 64.810.0181.15 ± 14.230.773
Placebo247.30 ± 73.20244.28 ± 76.66−0.84 ± 17.62

Urine S. GP. major1020.60 ± 5.190.5771021.40 ± 5.080.827−0.07 ± 0.510.607
Placebo1021.21 ± 6.901021.87 ± 7.80−0.06 ± 0.44

Ultrasound grade n (%)P. major/placebo31/320.572231/32
Grade 00/03 (9.6)/00.0382
Grade 19 (29.1)/7 (21.9)17 (54.8)/8 (25)
Grade 222 (70.9)/25 (78.1)11 (35.5)/23 (71.9)
Grade 30/00/1 (3.1)

1Mann–Whitney U test; 2Pearson chi-square. ALT, alanine aminotransferase; AST, aspartate aminotransferase; FBS, fasting blood sugar; CHOL, cholesterol; TG, triglyceride; HDL, high-density lipoprotein; LDL, low-density lipoprotein; SG, specific gravity of urine; negative sign, increase.